Proof that lower is better - LDL cholesterol and IMPROVE-IT

New England Journal of Medicine

Volumn 372, Issue 25, 2015, Pages 2448-2450

  Jarcho, John A ^b   Keaney, John F ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PLACEBO; ROSUVASTATIN; SIMVASTATIN; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; EDITORIAL; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MONOTHERAPY; NONHUMAN; PLEIOTROPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; THERAPY EFFECT; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; BLOOD; FEMALE; MALE;

ACUTE CORONARY SYNDROME; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; SIMVASTATIN;

EID: 84931375227     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1507041     Document Type: Editorial

References (12)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
2. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: Suppl 1: III39-III43.
3. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-74.
4. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
5. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended- release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371: 203-12.
6. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-99.
7. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
8. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-82.
9. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: Suppl 2: S1-S45.
10. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97.
11. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99.
12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9.